Although the cardiac stent market is becoming more competitive with the entry of new products from Abbott Labs (ABT - Get Report) and Medtronic (MDT - Get Report), Boston Scientific remains the market share leader. It is also seeing strong results for cardiac rhythm management products, with sales rising more than 10% year over year in the third quarter. As the economy recovers and continues to pay down debt, I look for this stock to be a top performer in the medical devices sector next year.
As usual, I am going to run out of room before I run out of stocks to talk about, but I want to mention some other companies with high scores that you should look into. Electro Scientific (ESIO - Get Report) just settled with activist investor David Nierenberg of D3 Partners about the voting rights of his 15% interest in the company. D3 is pushing the company to use its $150 million cash stockpile to buy back stock. The fund has a record of winning these battles and increasing shareholder value.
Sunstone Hotel Investors (SNO) also made the list of companies with high scores on the scale. I believe it is the very best of the lodging REITS, with great brands and a strong balance sheet. At these levels, even if I am early, the dividend makes it worth the wait.